Imaging startup Clairity is lauding a National Comprehensive Cancer Network (NCCN) update to its 2026 clinical practice guidelines for breast cancer screening and diagnosis to include AI-based mammogram analysis for assessing a woman's five-year breast cancer risk.
The updated guidelines introduce a five-year breast cancer risk threshold of 1.7% or higher, informed by AI-based mammogram analysis, as a criterion for identifying women at increased risk. Specific additions include linking risk assessment directly to clinical actions such as supplemental imaging and risk-reduction strategies, calling for periodic reassessment over time, and expanding identification of increased-risk individuals starting at age 35.
Clairity's Clairity Breast model is the first model cleared by the U.S. Food and Drug Administration for predicting five-year breast cancer risk using AI-based mammography analysis and is currently the only such model available for commercial use, Clairity noted.
